2008
DOI: 10.1016/j.ejmech.2007.09.006
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis and anticancer activity of lipophilic platinum(II) complexes of 3,5-diisopropylsalicylate

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
10
0

Year Published

2010
2010
2015
2015

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 30 publications
(10 citation statements)
references
References 20 publications
0
10
0
Order By: Relevance
“…One of the earliest leads in the development of Pt complexes with activity in resistant tumor cells was a series of complexes with 1,2-diaminocyclohexane (DACH) carrier ligand (Burchenal et al 1978;Burchenal et al 1979). Consequently many substituted DACH complexes have been evaluated (Chaney 1995;Kidani 1991;Hoeschele et al 1994) for their cytotoxicity and some of them have entered into preclinical and clinical trials (Yu et al 2006;Liu et al 2007;Rothenburger et al 2006;Yu et al 2008). Thus, it can be deduced that 1R,2R-DACH is an effective carrier group in designing DACH-type platinum derivatives.…”
Section: Introductionmentioning
confidence: 97%
“…One of the earliest leads in the development of Pt complexes with activity in resistant tumor cells was a series of complexes with 1,2-diaminocyclohexane (DACH) carrier ligand (Burchenal et al 1978;Burchenal et al 1979). Consequently many substituted DACH complexes have been evaluated (Chaney 1995;Kidani 1991;Hoeschele et al 1994) for their cytotoxicity and some of them have entered into preclinical and clinical trials (Yu et al 2006;Liu et al 2007;Rothenburger et al 2006;Yu et al 2008). Thus, it can be deduced that 1R,2R-DACH is an effective carrier group in designing DACH-type platinum derivatives.…”
Section: Introductionmentioning
confidence: 97%
“…Basically, the platinum(II) oxaliplatin derivatives can be divided into two groups. The first one involves dachbased platinum(II) complexes containing various isomers and derivatives of 1,2-diaminocyclohexane (dach) as N-donor carrier ligands, while a leaving group differs from the oxalate dianion [5][6][7]. The second one comprises the platinum(II) oxalato complexes with bidentate oxalate dianion as a leaving group, and on the other hand, the carrier N-donor ligand differs from dach [8][9][10][11][12][13].…”
Section: Introductionmentioning
confidence: 99%
“…The test compound, dissolved in cell culture medium, was added in final concentrations ranging from 0 to 100 lM. After 72 h, the cellular survival was evaluated by using sulforhodamine B (SRB) assay [14]. The optical density was read at 490 nm.…”
Section: Synthesismentioning
confidence: 99%